Amy Mcbride  Wendell net worth and biography

Amy Wendell Biography and Net Worth

Director of AxoGen

Ms. Wendell has served as a member of our Board of Directors since September 2016 and Lead Director since May 2018. She was a senior advisor for the healthcare investment banking practice of Perella Weinberg Partners (“PWP”) from January 2016 through April 2019. Her scope of responsibilities involved providing guidance and advice with respect to mergers and acquisitions and divestitures for clients and assisting PWP in connection with firm-level transactions. From 2015 until October 2018, Ms. Wendell served as a senior advisor for McKinsey and Company’s (“McKinsey”) strategy and corporate finance practice and as a member of McKinsey’s transactions advisory board to help define trends in mergers and acquisitions, as well as help shape McKinsey’s knowledge agenda. From 1986 until January 2015, Ms. Wendell held various roles of increasing responsibility at Covidien plc (“Covidien”) (including its predecessors, Tyco Healthcare and Kendall Healthcare Products), including in engineering, product management and business development. Most recently, from December 2006 until Covidien’s acquisition by Medtronic plc in January 2015, Ms. Wendell served as Covidien’s Senior Vice President of Strategy and Business Development, where she managed all business development, including acquisitions, equity investments, divestitures and licensing/distribution, and led Covidien’s strategy and portfolio management initiatives. Ms. Wendell is a member of the board of directors of Hologic, Inc. (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products with a strong position in women’s health, Baxter International, Inc. (NYSE: BAX), a leading global medical products company and on the board of Solventum Corp. (NASDAQ SOLV) the recent healthcare spin-off of 3M. Ms. Wendell holds a M.S. in biomedical engineering from the University of Illinois and a B.S. in mechanical engineering from Lawrence Institute of Technology (n/k/a Lawrence Technological University). Ms. Wendell’s qualifications to serve on our Board of Directors include her broad healthcare management and governance experience, as well as her knowledge of healthcare policy.

What is Amy Mcbride Wendell's net worth?

The estimated net worth of Amy Mcbride Wendell is at least $3.27 million as of March 3rd, 2025. Wendell owns 97,899 shares of AxoGen stock worth more than $3,266,694 as of December 4th. This net worth estimate does not reflect any other investments that Wendell may own. Learn More about Amy Mcbride Wendell's net worth.

How do I contact Amy Mcbride Wendell?

The corporate mailing address for Wendell and other AxoGen executives is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. AxoGen can also be reached via phone at (386) 462-6800 and via email at [email protected]. Learn More on Amy Mcbride Wendell's contact information.

Has Amy Mcbride Wendell been buying or selling shares of AxoGen?

Amy Mcbride Wendell has not been actively trading shares of AxoGen within the last three months. Most recently, Amy Mcbride Wendell sold 5,000 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $20.02, for a transaction totalling $100,100.00. Following the completion of the sale, the director now directly owns 97,899 shares of the company's stock, valued at $1,959,937.98. Learn More on Amy Mcbride Wendell's trading history.

Who are AxoGen's active insiders?

AxoGen's insider roster includes P Burke (Director), Erick Devinney (Insider), Michael Donovan (VP), Gregory Freitag (Director), Peter Mariani (CFO), Maria Martinez (Insider), Guido Neels (Director), Joseph Tyndall (Director), Amy Wendell (Director), and Karen Zaderej (CEO). Learn More on AxoGen's active insiders.

Are insiders buying or selling shares of AxoGen?

In the last twelve months, insiders at the medical equipment provider sold shares 16 times. They sold a total of 173,773 shares worth more than $3,429,182.24. The most recent insider tranaction occured on November, 11th when Director William P Mr. Burke sold 3,591 shares worth more than $86,255.82. Insiders at AxoGen own 2.8% of the company. Learn More about insider trades at AxoGen.

Information on this page was last updated on 11/11/2025.

Amy Mcbride Wendell Insider Trading History at AxoGen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/3/2025Sell5,000$20.02$100,100.0097,899View SEC Filing Icon  
9/6/2023Buy10,000$6.22$62,200.0080,342View SEC Filing Icon  
6/13/2019Buy5,000$20.25$101,250.0023,333View SEC Filing Icon  
8/14/2018Buy5,000$36.89$184,450.0018,333View SEC Filing Icon  
10/7/2016Buy13,333$7.50$99,997.5013,333View SEC Filing Icon  
See Full Table

Amy Mcbride Wendell Buying and Selling Activity at AxoGen

This chart shows Amy Mcbride Wendell's buying and selling at AxoGen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AxoGen Company Overview

AxoGen logo
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
Read More

Today's Range

Now: $32.85
Low: $30.24
High: $34.24

50 Day Range

MA: $21.72
Low: $15.59
High: $32.85

2 Week Range

Now: $32.85
Low: $9.22
High: $34.24

Volume

3,164,205 shs

Average Volume

740,537 shs

Market Capitalization

$1.52 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06